Physician profile
Stephen J Murphy
NPI 1700932316
$3,468.79
in general payments reported to CMS, 2019-2025
20 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $419 · 2021: $707 · 2022: $671 · 2023: $196 · 2024: $51.52 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528 · Education: $18.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.26 |
| Education | $18.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $738.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $560.38 | 2019-2025 | Benlysta |
| Amgen INC. | $445.50 | 2019-2025 | Tavneos, Uplizna |
| Novartis Pharmaceuticals Corporation | $434.79 | 2019-2025 | |
| Pfizer INC. | $383.15 | 2019-2022 | |
| Genentech USA, INC. | $196.49 | 2019-2023 | Actemra, Rituxan |
| Ucb, INC. | $150.94 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $122.09 | 2019 | |
| Lilly USA, LLC | $92.76 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $76.15 | 2021-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $37.89 | 2022 | |
| Sebela Pharmaceuticals INC. | $36.25 | 2019 | |
| Hikma Pharmaceuticals USA | $36.25 | 2019 | |
| Genzyme Corporation | $31.34 | 2025 | |
| Antares Pharma, INC. | $29.87 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $23.13 | 2019-2020 | |
| Horizon Therapeutics Plc | $20.90 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $20.43 | 2024 | Saphnelo |
| Celltrion USA INC. | $18.51 | 2023 | Yuflyma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.